300482 万孚生物
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,575,2505.82%2,764,9145,680,5133,361,0432,810,841
减:营业总成本1,184,2603.35%2,294,6514,330,0262,756,3692,007,769
    其中:营业成本561,6973.53%1,033,7712,736,6261,396,076870,750
               财务费用(5,800)-56.70%(6,405)(698)48,92127,971
               资产减值损失----(11,522)(78,975)(5,874)(116,115)
公允价值变动收益15,5735,272.86%14,79912,81210,551237
投资收益(1,212)-105.45%31,10059,77347,46831,944
    其中:对联营企业和合营企业的投资收益(7,336)580.74%(4,333)3,2391,263(1,423)
营业利润407,2214.90%549,1381,367,732691,897740,092
利润总额405,3464.85%540,7631,364,526680,489730,934
减:所得税费用47,031-12.54%53,334174,40647,908114,127
净利润358,3157.66%487,4281,190,120632,580616,807
减:非控股权益2,515-249.68%(196)(6,943)(1,853)(17,363)
股东净利润355,8006.37%487,6251,197,063634,433634,170

市场价值指针
每股收益 (元) *0.7802.63%1.1002.7101.4301.440
每股派息 (元) *----0.4000.5000.3000.500
每股净资产 (元) *11.16913.08%9.9179.5307.2947.980
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容